

# PPSV23 (Pneumovax®)

Vaccine	Dosage & Administration	Primary Schedule	Recommended Age	Indication for Use
PPSV23 (Pneumovax®23) <i>Merck</i>	0.5 mL IM	Single dose with revaccination of some individuals*	2 years and older	Vaccination against invasive pneumococcal disease types included in the vaccine



## Pneumococcal Polysaccharide (PPSV23) Vaccine Recommendations:

- Persons 2-64 years of age who have a chronic health problem (See Table 1)
- \*Persons 2-64 years of age who are immunocompromised, have cerebrospinal fluid (CSF) leaks or cochlear implants (See Table 1)
- Adults 19-64 years of age who: Have asthma, smoke cigarettes (should receive smoking cessation counseling) or experiencing alcoholism
- All adults ≥ 65 years of age should routinely receive a single dose of PPSV23

## PPSV23 Recommendations for High-Risk Children Previously Immunized with pneumococcal conjugate vaccine (PCV13):

- DO NOT administer PCV13 and PPSV23 at the same time
- Children who have previously received PCV13 and are among risk groups for which PPSV23 is recommended should receive 1 dose of PPSV23 at age 2 years (at least 8 weeks after the last dose of PCV13), as they will benefit from additional pneumococcal serotype immunity stimulated by PPSV23 (See Table 2)
- Immunocompromised children should receive a 2nd dose of PPSV23 five years after the 1st dose of PPSV23
- Complete PCV13 and/or PPSV23 vaccination at least 2 weeks prior to surgery or initiation of therapy when elective splenectomy, immunocompromising therapy, or cochlear implant placement is planned

**Advisory Committee on Immunization Practices (ACIP) Recommendations for PCV13 and PPSV23 Use in Immunocompromised Children Aged 6-18 years:** For more information see [http://publichealth.lacounty.gov/ip/providers/B71/B71\\_PCV.pdf](http://publichealth.lacounty.gov/ip/providers/B71/B71_PCV.pdf)

- **PPSV23-naïve children:** ACIP recommends that children aged 6-18 years who are immunocompromised, have CSF leaks or cochlear implants who have not received PCV13 receive a single PCV13 dose first, followed by a dose of PPSV23 eight weeks later
- **Previous vaccination with PPSV23:** Children 6 through 18 years who are immunocompromised, have CSF leaks or cochlear implants who have not received PCV13, and who previously received 1 dose of PPSV23 should receive a single PCV13 dose 8 weeks after the last PPSV23 dose, even if they have received PCV7. If indicated give a 2<sup>nd</sup> PPSV23 dose 5 years after the first PPSV23 dose. These children should not receive more than 2 doses of PPSV23 before age 65 years.

## Contraindications

- A serious allergic reaction to a vaccine component or following a prior dose
- Pregnancy

## Precautions

- A moderate or severe acute illness until condition improves or resolves

## Adverse Reactions

- **Local:** redness or pain at administration site
- **Systemic:** fever, muscle aches, or more severe local reactions

## Storage & Handling

- Store vaccine between 35° and 46°F (aim for 40°F)
- DO NOT freeze vaccine



IP-B71-VPPSV-V2 (12/12/19)

Table 1.

Chronic Conditions	Immunocompromising/High Risk Conditions
Heart, lung or liver disease, diabetes,	Anatomic or functional asplenia; CSF leaks; chronic renal failure; cochlear implant; congenital or acquired immunodeficiency; HIV infection; Hodgkin disease; leukemias, lymphomas & other diseases; malignant neoplasms; multiple myeloma; nephrotic syndrome; Sickle cell disease & other hemoglobinopathies; solid organ transplantation

Table 2.

AGE	NUMBER OF PCV13 DOSES RECEIVED	NUMBER OF RECOMMENDED PPSV23 DOSES
24-71 months with an underlying medical condition	2 doses received – 3rd dose 8 weeks after the most recent dose and 4th dose 8 weeks later	1 dose at least 8 weeks after the last dose of PCV13
	1 dose received – 2 <sup>nd</sup> dose 8 weeks after the most recent dose	1 dose of PPSV23 at least 8 weeks later

### Use of PPSV23 and PCV13 in high-risk adults ≤ 65 years:

- DO NOT administer PCV13 and PPSV23 at the same time, the minimum interval between PCV13 and PPSV23 is 8 weeks
- Adults ≤ 64 years of age who are immunocompromised (See Table 1)
- Administer pneumococcal conjugate vaccine (PCV13) first. Instruct patient to return in 8 weeks for PPSV23
- If PPSV23 is given first, wait 1 year before giving PCV13
- The patient should receive a 2nd dose of PPSV23 five years after the 1st dose of PPSV23

### Recommendations for routine use of PPSV23 and PCV13 in adults ≥65 years:

- DO NOT administer PCV13 and PPSV23 at the same time
- **All Adults aged ≥65 years who received PPSV23 before age 65 years for any indication:** Administer a 2<sup>nd</sup> dose of PPSV23 five years after the 1<sup>st</sup> dose. Do NOT administer additional doses of PPSV23 following the dose administered at age ≥65 years.
- In June 2019, the ACIP no longer routinely recommends PCV13 for all immunocompetent adults aged ≥65 years, who do NOT have CSF leak, or cochlear implant and who have not previously received PCV13. The ACIP recommends PCV13 based on shared clinical decision-making\*\*.
- **Shared Clinical Decision-Making for PCV13 for all immunocompetent adults aged ≥65 years, who do NOT have CSF leak, or cochlear implant:** If the patient resides in a nursing home, other long-term care facility, in a setting with low pediatric PCV13 uptake, or traveling to settings with no pediatric PCV13 program administer PCV13 one year prior to PPSV23
- **Adults aged ≥65 years who are immunocompromised, have CSF leaks or cochlear implants and have NOT previously received pneumococcal vaccine or whose previous vaccination history is unknown:** Administer PCV13. Instruct patient to return in 8 weeks for PPSV23.
- **Adults aged ≥65 years who are immunocompromised, have CSF leaks or cochlear implants and have previously received pneumococcal vaccine PPSV23:** Administer one PCV13 dose ≥1 year after the last PPSV23 dose. If PCV13 was given before age 65 years, no additional PCV13 is needed.

#### Reference:

\*\* Matanock A, Lee G, Gierke R, et al.; Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:1069-75. [https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6846-h.pdf?deliveryName=USCDC\\_921-DM13663](https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6846-h.pdf?deliveryName=USCDC_921-DM13663). Accessed 11/22/19.

